文献速递前列腺癌

尿液精胺及精胺风险评分预测高级别前列腺癌

Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-01-06

精胺与前列腺癌及高级别前列腺癌(HGPCa)风险负相关,基于PSA、前列腺体积、DRE和精胺的精胺风险评分对HGPCa的AUC达0.82。在90%敏感性下可避免36.7%穿刺和24.4%ISUP 1级诊断,阴性预测值95.4%。

要点

  • 尿液精胺水平越低,前列腺癌和高级别前列腺癌风险越高
  • 精胺风险评分(含PSA、前列腺体积、DRE、精胺)对HGPCa的AUC为0.82
  • 90%敏感性下可避免36.7%穿刺,阴性预测值95.4%

核心结论

  • 尿液精胺及精胺风险评分可识别高级别前列腺癌高风险男性,减少不必要的穿刺。

研究设计与样本

  • 穿刺前收集尿液(未行前列腺按摩),采用UPLC-MS/MS检测精胺水平。

主要发现

  • 600名男性中前列腺癌检出率30.8%(185/600),高级别前列腺癌(ISUP≥2)检出率17.2%(103/600)。
  • 精胺最低四分位组与最高四分位组相比,前列腺癌风险为49.3% vs. 16.7%,ISUP≥2风险为31.3% vs. 8.7%。
  • 多因素分析显示PSA、前列腺体积、DRE和精胺为独立预测因子,精胺风险评分对前列腺癌AUC为0.78,对HGPCa AUC为0.82。
  • 在HGPCa 90%敏感性下,可避免36.7%的穿刺和24.4%的ISUP 1级诊断,阴性预测值为95.4%。
  • 决策曲线分析显示精胺风险评分有净临床获益,内部验证(bootstrapping)显示良好区分度和校准度。

关键数值与推荐

  • 精胺风险评分对HGPCa的AUC为0.82,对前列腺癌的AUC为0.78。
  • 90%敏感性下可避免36.7%穿刺和24.4%ISUP 1级诊断,阴性预测值95.4%。

临床怎么用

  • 对于PSA 4-20 ng/mL的男性,可考虑检测穿刺前尿液精胺并结合PSA、前列腺体积和DRE计算精胺风险评分。
  • 精胺风险评分有助于识别HGPCa高风险者,并在90%敏感性下减少不必要的穿刺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the role of urine spermine and Spermine Risk Score in prediction of high-grade prostate cancer (HGPCa, ISUP grade group ≥2). METHODS: Nine hundred and five consecutive men with elevated PSA were prospectively recruited from two hospitals. Core analyses focused on consecutive men with PSA 4-20 ng/mL (n = 600). Pre-biopsy urine without prior prostatic massage was analyzed for spermine level with ultra-high performance liquid chromatography with triple quadrupole mass spectrometer (UPLC-MS/MS). The proportions of PCa and HGPCa were compared across different spermine ranges. Logistic regressions were used to form different models, and their performances were compared using area under curve (AUC) and decision curve analysis (DCA). RESULTS: PCa and HGPCa were diagnosed in 30.8% (185/600) and 17.2% (103/600) men, respectively, and were significantly associated with lower urine spermine levels. Between the lowest and highest quartiles of spermine results, a threefold increase in PCa risk (49.3% vs. 16.7%) and 3.5-fold increase in ISUP grade group ≥2 PCa risk (31.3% vs. 8.7%) were observed. Multivariate analysis showed PSA, prostate volume (PV), digital rectal examination (DRE), and spermine, which were independent predictors for PCa and HGPCa, and a Spermine Risk Score with these factors achieved the highest AUC of 0.78 for PCa and 0.82 for HGPCa. At 90% sensitivity for HGPCa, 36.7% biopsies and 24.4% ISUP grade group 1 diagnoses could have been avoided, with a negative predictive value of 95.4%. DCA revealed net clinical benefit of the Spermine Risk Score. Internal validation with bootstrapping showed good discrimination and calibration. CONCLUSION: Urine spermine and Spermine Risk Score identified men at higher risk of HGPCa and reduced unnecessary biopsies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Fung YH, Teoh JY, et al. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33408349. doi:10.1038/s41391-020-00312-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。